Endometrial cancer medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
{| class="wikitable" | {| class="wikitable" | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Risk | ||
| Line 29: | Line 28: | ||
| style="background:#F5F5F5;" align="center" + |Giving adjuvant brachytherapy for the high risk early staged tumors depends on patient and provider preferences | | style="background:#F5F5F5;" align="center" + |Giving adjuvant brachytherapy for the high risk early staged tumors depends on patient and provider preferences | ||
|} | |} | ||
==References== | ==References== | ||
Revision as of 16:14, 29 November 2018
|
Endometrial cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Endometrial cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Endometrial cancer medical therapy |
|
Risk calculators and risk factors for Endometrial cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The optimal therapy for endometrial cancer depends on the stage at diagnosis. A combination of chemotherapy and radiation therapy is indicated in stages IIIB- IV.
Medical Therapy
| Risk | Risk definition | Management | Additional notes |
|---|---|---|---|
| Low risk | • Stage IA endometrial cancer • Well differentiated endometroid histology • Tumor confined to endometrium |
Total hysterectomy, bilateral salpingo-oophorectomy, and lymph node evaluation | • Women that opt for preservation of fertility may be candidates for medical therapy • Adjuvant therapy not indicated |
| Intermediate risk | • Stage I (tumor invades myometrium) or • Stage II (tumor demonstrates cervical stroma invasion) • Tumor usually moderately differentiated or poorly differentiated |
• Total hysterectomy, bilateral salpingo-oophorecomy, and lymph node evaluation • Adjuvant radiotherapy is indicated for patients with risk factors |
• No data available to recommend adjuvant chemotherapy in these patients • Observation recommended instead of adjuvant radiotherapy if patient has no risk factors |
| High risk | • Stage III or higher or • Any stage with serous or clear cell carcinoma |
• For stage I and II, surgery may be followed by adjuvant vaginal brachytherapy • For stage III and IV, surgery should be followed by adjuvant chemotherapy and pelvic radiotherapy |
Giving adjuvant brachytherapy for the high risk early staged tumors depends on patient and provider preferences |